Evidence map›Paper›PMID 26508503›Full record

Trial reportZeitschrift fur Rheumatologie2016

Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.

Z Xia, J Lyu, N Hou, L Song, X Li, H Liu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Zeitschrift fur Rheumatologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 7 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 7 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Z XiaDepartment of Rheumatology, Shandong University Qilu Hospital, 107 Wenhua Xi Road, 250012, Jinan, Shandong Province , China.
J LyuDepartment of Internal Medicine, Dezhou People's Hospital, Dezhou, China.
N HouDepartment of Rheumatology, Shandong University Qilu Hospital, 107 Wenhua Xi Road, 250012, Jinan, Shandong Province , China.
L SongDepartment of Rheumatology, Shandong University Qilu Hospital, 107 Wenhua Xi Road, 250012, Jinan, Shandong Province , China.
X LiDepartment of Rheumatology, Shandong University Qilu Hospital, 107 Wenhua Xi Road, 250012, Jinan, Shandong Province , China.
H LiuDepartment of Rheumatology, Shandong University Qilu Hospital, 107 Wenhua Xi Road, 250012, Jinan, Shandong Province , China. huaxiangliu@hotmail.com.
Qilu Hospital of Shandong University · CNDezhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a potentially destructive disease that may have a profound impact on patients' function and quality of life. RA therapy is still a challenge for rheumatologists; however, new antirheumatic drugs may be a treatment option for disease-modifying antirheumatic drug (DMARD)-experienced patients with active RA.

objectivesThe present study is a prospective trial that aims to investigate the effects of therapy with iguratimod plus methotrexate (MTX) in comparison with iguratimod or MTX monotherapy in DMARD-experienced adult patients with active RA.

methodsA total of 131 patients (24 men, 107 women, mean age 46.63 ± 10.61 years) with a history of being treated with traditional DMARDs were investigated. In all, 44 patients were treated with iguratimod (25 mg, twice daily, orally) plus MTX (a weekly dose of 10 mg, orally), 38 patients received iguratimod (25 mg, twice daily, orally), or 49 patients received MTX (weekly dose of 10 mg, orally) for 24 weeks.

resultsA therapeutic effect with iguratimod was observed between 4 and 10 weeks after treatment initiation and was effective even in patients who had a poor response to previous treatment with DMARDs. The combination of iguratimod with MTX was superior to iguratimod or MTX monotherapy.

conclusionThe data imply that iguratimod is a welcome addition to the small-molecule drug therapy for DMARD-experienced patients with active RA. Iguratimod (alone or in combination with MTX) is an emerging option for the treatment of DMARD-experienced adult patients with active RA who have had an inadequate response to or are intolerant of other DMARDs.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAttitude of Health PersonnelChinaChromonesDose-Response Relationship, DrugDrug CombinationsEvidence-Based MedicineFemaleHumansImmunosuppressive AgentsMaleMethotrexateMiddle AgedPatient SatisfactionPrevalenceAntirheumatic AgentsChromonesDrug CombinationsiguratimodImmunosuppressive AgentsMethotrexateSulfonamidesAntirheumatic agentsAutoimmune diseasesImmunosuppressive agentsQuality of lifeTreatment outcome

Identifiers

PMID26508503
OpenAlexW2181564511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.